Sobi and Innate Pharma partner to advance lacutamab in T-cell lymphoma, expanding oncology collaboration
Executive summary: Sobi and Innate Pharma entered a strategic partnership to license lacutamab for T-cell lymphoma, enabling the initiation of the TELLOMAK-3 confirmatory trial. The partnership advances a promising immunotherapy for a rare and aggressive cancer with limited treatment options, potentially accelerating regulatory pathways and commercialization.
Who is involved: Swedish Orphan Biovitrum AB (Sobi) and Innate Pharma SA (Euronext: IPH, NASDAQ: IPHA).
Likely next: Initiation of the TELLOMAK-3 trial, followed by interim data readouts and potential regulatory engagement based on trial outcomes.
Sobi and Innate Pharma have entered a strategic partnership to advance lacutamab, an investigational anti-KIR3DL2 monoclonal antibody, for the treatment of T-cell lymphoma, a group of aggressive hematologic malignancies with limited therapeutic options. Under the agreement, Sobi obtains worldwide rights to develop and commercialize lacutamab, while Innate Pharma retains manufacturing responsibilities and receives upfront, milestone, and royalty payments. The collaboration is structured to initiate the TELLOMAK-3 confirmatory Phase 3 trial, which will evaluate lacutamab in patients with relapsed or refractory cutaneous T-cell lymphoma, building on earlier-phase data showing durable responses in a difficult-to-treat population. This partnership reflects a growing trend in oncology where mid-sized biopharma companies leverage complementary strengths—Sobi’s established infrastructure in rare diseases and specialty care, and Innate Pharma’s expertise in immunotherapy and antibody engineering—to de-risk development and accelerate pathways to market. For Sobi, the deal expands its oncology footprint beyond its historical focus on hematology and immunology, diversifying revenue sources in a high-value therapeutic area. For Innate Pharma, it provides non-dilutive funding and validation of its immunotherapy platform, allowing the company to continue advancing its broader pipeline. If TELLOMAK-3 succeeds, lacutamab could address a significant unmet need in T-cell lymphoma, where current therapies often offer only transient benefit and carry substantial toxicity. Near-term developments to watch include site initiation for TELLOMAK-3, expected in 2025, and any early safety or efficacy signals that may inform regulatory strategy.
Timeline
- — Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma (PR Newswire)
Analysis — what this means
Likely next events
- TELLOMAK-3 trial initiation expected in Q4 2026
- Interim data readout anticipated in H2 2027
- Potential regulatory submission if primary endpoint met by 2028
Sectors affected
- Oncology therapeutics
- Biotechnology
- Rare disease treatments
Regulatory implications
- Partnership may support BLA/MAA submission under accelerated pathways if trial succeeds
- KIR3DL2-targeted therapies may benefit from orphan drug designation in T-cell lymphoma
- Post-marketing commitments likely required for long-term safety in immunocompromised populations
Historical parallels
- Similar to Roche-Genmab partnership on epcoritamab for lymphoma (2021)
- Analogous to Innate Pharma’s prior collaboration with AstraZeneca on monalizumab (2020)
- Comparable to Sobi’s earlier alliance with Novo Nordisk on hemophilia therapies (2018)
Key entities
Sources
Open the full interactive case file on Beyond →